Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.

Matériel viral, dans l'état d'isolement ou épuré, dans lequel le génome comporte un ordre de nucléotide choisi du groupe comprenant l'identification SEQ NO:46 d'ordres, l'identification SEQ NO:51, l'identification SEQ NO:52, l'identification SEQ NO:53 et l'identification SEQ NO:56, leurs ordres complémentaires et leurs ordres équivalents, en particulier ordres de nucléotide montrant, pour n'importe quelle succession de 100 monomères contigus, au moins 50% et de préférence au moins homologie de 70% avec l'identification SEQ NO:46 de lesdits ordres, l'identification SEQ NO:51, l'identification SEQ NO:52, l'identification SEQ NO:53 et l'identification SEQ NO:56, respectivement, et leurs ordres complémentaires.

 
Web www.patentalert.com

< Malaria vaccine

< Fulvic acid and its use in the treatment of various conditions

> DNA encoding the T cell surface protein CD4 and use of fragments of CD4 in the treatment of AIDS

> Cold-adapted equine influenza viruses

~ 00076